文献速递胸部肿瘤放疗

无进展死亡作为描述局部晚期非小细胞肺癌心脏放疗效应的终点指标

Death without progression as an endpoint to describe cardiac radiation effects in locally advanced non-small cell lung cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2023-01-13

该研究回顾性分析单中心187例2008至2016年接受根治性放化疗的局部晚期或少转移非小细胞肺癌患者,以无癌症进展死亡(DWP)为主要终点进行竞争风险回归,发现平均心脏剂量≥10 Gy与DWP升高及总生存期缩短相关,心室和心包剂量与DWP相关,外部队列验证了心室剂量与DWP的关联。

要点

  • 平均心脏剂量≥10 Gy组5年DWP率为16.9%,低于10 Gy组为6.7%(p=0.04)。
  • 平均心脏剂量≥10 Gy组中位总生存期为22.9个月,低于10 Gy组的34.1个月(p<0.001)。
  • 右心室平均剂量≥5.5 Gy被识别为DWP的预测因子。

核心结论

  • 心血管亚结构剂量与DWP呈现不同关联,未来非小细胞肺癌心脏毒性研究可考虑将DWP作为终点。

研究设计与样本

  • 回顾性 review 了2008至2016年在单中心接受根治性放化疗的187例局部晚期或少转移性非小细胞肺癌患者记录,并纳入另一机构的140例外部队列。
  • 提取心脏、肺及十个心血管亚结构的剂量学参数,采用排除非小细胞肺癌诊断的Charlson共病指数(CCI)将患者分为CCI低(0-2;n=66)、CCI中(3-4;n=78)和CCI高(≥5;n=43)组。
  • 主要终点为DWP,采用竞争风险回归建模;次要终点包括总生存期。

主要发现

  • 中位随访时间对于存活者为7.3年,143例(76.5%)死亡,其中进展后死亡118例(63.1%),DWP 25例(13.4%)。
  • 多变量分析中, increasing CCI分层和平均心脏剂量与DWP相关。
  • 平均心脏剂量≥10 Gy vs <10 Gy,DWP较高(5年率,16.9% vs 6.7%,p=0.04),总生存期较差(中位,22.9 vs 34.1个月,p<0.001)。
  • 心室(左、右及双侧)和心包剂量与DWP相关,而心房亚结构剂量不相关;三者均与总生存期呈反向关联。
  • 切点分析识别右心室平均剂量≥5.5 Gy为DWP的预测因子;外部队列证实心室剂量而非心房剂量与DWP的关联。

关键数值与推荐

  • 平均心脏剂量≥10 Gy vs <10 Gy,DWP的5年率为16.9% vs 6.7%(p=0.04)。
  • 平均心脏剂量≥10 Gy vs <10 Gy,中位总生存期为22.9 vs 34.1个月(p<0.001)。
  • 右心室平均剂量≥5.5 Gy被识别为DWP的预测因子。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Prior studies have examined associations of cardiovascular substructure dose with overall survival (OS) or cardiac events after chemoradiotherapy (CRT) for non-small cell lung cancer (NSCLC). Herein, we investigate an alternative endpoint, death without cancer progression (DWP), which is potentially more specific than OS and more sensitive than cardiac events for understanding CRT toxicity. MATERIALS AND METHODS: We retrospectively reviewed records of 187 patients with locally advanced or oligometastatic NSCLC treated with definitive CRT from 2008 to 2016 at a single institution. Dosimetric parameters to the heart, lung, and ten cardiovascular substructures were extracted. Charlson Comorbidity Index (CCI), excluding NSCLC diagnosis, was used to stratify patients into CCI low (0-2; n = 66), CCI intermediate (3-4; n = 78), and CCI high (≥5; n = 43) groups. Primary endpoint was DWP, modeled with competing risk regression. Secondary endpoints included OS. An external cohort consisted of 140 patients from another institution. RESULTS: Median follow-up was 7.3 years for survivors. Death occurred in 143 patients (76.5 %), including death after progression in 118 (63.1 %) and DWP in 25 (13.4 %). On multivariable analysis, increasing CCI stratum and mean heart dose were associated with DWP. For mean heart dose ≥ 10 Gy vs < 10 Gy, DWP was higher (5-year rate, 16.9 % vs 6.7 %, p = 0.04) and OS worse (median, 22.9 vs 34.1 months, p < 0.001). Ventricle (left, right, and bilateral) and pericardial but not atrial substructure dose were associated with DWP, whereas all three were inversely associated with OS. Cutpoint analysis identified right ventricle mean dose ≥ 5.5 Gy as a predictor of DWP. In the external cohort, we confirmed an association of ventricle, but not atrial, dose with DWP. CONCLUSION: Cardiovascular substructure dose showed distinct associations with DWP. Future cardiotoxicity studies in NSCLC could consider DWP as an endpoint.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yegya-Raman N, Kegelman TP, Ho Lee S, et al. Death without progression as an endpoint to describe cardiac radiation effects in locally advanced non-small cell lung cancer. Clin Transl Radiat Oncol. 2023. PMID: 36691564. doi:10.1016/j.ctro.2023.100581

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。